Company / Cash & Equivalents
Omnicell Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$196.5M
FY2025
5-year range
$196.5M / $485.9M
FY2021-FY2025
Trend
-46.8%
vs FY2024
Sector context
#83 of 148
Health Care
What the data says
At $197M, Omnicell's cash & equivalents ranks #83 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $32M in FY2017 to $486M in FY2021.
Based on SEC 10-K filings.
$197M in FY2025 with a 5-year CAGR of +9.1%.
Declined from $468M to $197M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.4%
- 5-Year CAGR
- +9.1%
- 10-Year CAGR
- -
Sector benchmark
#83 of 148 in Health CareTop 56% of 148This company $196.5M Sector average $1.2B
▼
-83.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.1%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 46.8% year-over-year.
- Ranks #83 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $196.5M | -46.8% |
| FY2024 | $369.2M | -21.1% |
| FY2023 | $468.0M | +34.1% |
| FY2022 | $349.1M | -28.2% |
| FY2021 | $485.9M | +282.0% |
| FY2020 | $127.2M | +89.3% |
| FY2019 | $67.2M | +0.0% |
| FY2018 | $67.2M | +107.2% |
| FY2017 | $32.4M | -74.2% |
| FY2016 | $125.9M | +53.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026